一、审议通过了《关于向下修正"楚天转债"转股价格的议案》 鉴于 2024 年 4 月 11 日至 2024 年 5 月 27 日，公司股票已出现任意连续三 十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%（即 8.5 元/ 股）的情形，已触发"楚天转债"转股价格的向下修正条款。 为优化公司资本结构，维护投资者权益及促进公司的长期稳健发展，根据《深 圳证券交易所上市公司自律监管指引第 15 号——可转换公司债券》、公司《创业 板向不特定对象发行可转换公司债券募集说明书》等相关条款的规定及公司股价 实际情况，公司董事会提议向下修正"楚天转债"转股价格，并将该议案提交公 司股东大会审议。修正后的转股价格应不低于该次股东大会召开日前二十个交易 日公司股票交易均价和前一交易日公司股票交易均价之间的较高者。同时，修正 后的转股价格不得低于公司最近一期经审计的每股净资产值和股票面值。如股东 大会召开时上述指标高于本次调整前"楚天转债"的转股价格（10 元/股），则 "楚天转债"转股价格无需调整。 | 证券代码:300358 | 证券简称:楚天科技 | 公告编号:2024-048 | 号 | | --- | - ...

关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 | 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2024-043 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 楚天科技股份有限公司 特别提示 1.证券代码：300358 证券简称：楚天科技 2.债券代码：123240 债券简称：楚天转债 3.转股价格：10.00 元/股 4.转股期限：自 2024 年 8 月 6 日至 2030 年 1 月 30 日止（如遇法定节假日 或休息日延至其后的第一个工作日；顺延期间付息款项不另计息）。 5.根据《楚天科技股份有限公司创业板向不特定对象发行可转换公司债券募 集说明书》（以下简称"《募集说明书》"）规定：在本次发行的可转换公司债 券（以下简称"可转债"）存续期间，当公司股票在任意连续三十个交易日中至 少有十五个交易日的收盘价低于当期转股价格的 85%时，公司董事会有权提出转 股价格向下修正方案并提交公司股东大会表决。上述方 ...

Investment Rating - The report assigns a "Strong Buy" rating for the company, indicating that the stock is expected to outperform the market by more than 5% over the next six months [12][33]. Core Insights - The company reported a revenue of 6.85 billion yuan in 2023, a year-on-year increase of 6.3%, but the net profit attributable to shareholders decreased by 44.1% to 320 million yuan [1][14]. - In Q1 2024, the company experienced a revenue decline of 10.4% year-on-year, with a net loss of 20.87 million yuan, marking a 115.7% decrease compared to the previous year [1][14]. - The company is actively expanding its product offerings and has established several subsidiaries to enhance its industry chain, including high-end centrifuges and purification engineering [2]. Financial Performance - The company's gross profit margin for 2023 was 32.1%, with a net profit margin of 4.5% [14]. - The total assets of the company stood at 12.28 billion yuan, with a total market capitalization of 5.18 billion yuan [6]. - The company forecasts net profits of 200 million yuan, 230 million yuan, and 350 million yuan for 2024, 2025, and 2026, respectively [15][16]. Revenue and Growth Projections - The company expects a revenue decline of 8.97% in 2024, followed by a modest recovery in subsequent years with growth rates of 2.94% in 2025 and 9.58% in 2026 [16]. - The report highlights that the sales of sterile preparation solutions are projected to decrease by 25% in 2024, with a gradual recovery expected thereafter [8][18]. Industry Positioning - The company is enhancing its competitive position by diversifying its product lines and improving its service offerings across the pharmaceutical manufacturing sector [2][14]. - The report indicates that the overall industry outlook remains stable, with expectations of moderate growth in the coming years [12][23].

证券代码：300358 证券简称：楚天科技 楚天科技股份有限公司 投资者关系活动记录表 编号：2024-003 | 调研活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | 媒体采访  业绩说明会 | | | □新闻发布会 □路演活动 | | | 现场参观 □其他 | | 参与单位名称 | 通过线上参与楚天科技 2023 年度网上业绩说明会的投资者 | | 及人员姓名 | | | 时 间 | 2024 年 4 月 29 日 15:00-17:00 | | 地 点 | 上海证券报·中国证券网 https://roadshow.cnstock.com/ | | | 董事长兼总裁：唐岳 | | 上市公司接待 | 投资与发展总裁兼董事会秘书：周飞跃 | | 人员姓名 | 财经总裁兼财务总监：肖云红 | | | 独立董事：张早平 | | | 公司于 2024 年 4 月 29 日（星期一）下午 15:00-17:00 在上海证券 | | | 报·中国证券网 https://roadshow.cnstock.com/，举办 2023 年度 | | | 业绩说明会，本次业绩说明会采用网络 ...

| --- | --- | |-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥1,392,029,678.89, a decrease of 10.39% compared to the same period last year[3]. - The net profit attributable to shareholders was a loss of ¥20,871,739.14, representing a decline of 115.65% year-on-year[3]. - The net cash flow from operating activities was -¥459,497,946.67, a decrease of 38.66% compared to the previous year[3]. - Total operating revenue for Q1 2024 was CNY 1,392,029,678.89, a decrease of 10.4% compared to CNY 1,553,392,936.78 in the same period last year[30]. - Net profit for Q1 2024 was a loss of CNY 20,716,801.32, compared to a profit of CNY 134,572,400.59 in Q1 2023, representing a significant decline[31]. - The company reported a total comprehensive loss of CNY -50,418,878.54 for Q1 2024, compared to a comprehensive income of CNY 144,762,047.17 in Q1 2023[32]. - Other comprehensive income after tax was a loss of CNY -29,702,077.22, compared to a gain of CNY 10,189,646.58 in the same period last year[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥12,283,563,726.34, an increase of 5.33% from the end of the previous year[3]. - The total liabilities as of March 31, 2024, were CNY 6,725,000,000.00, compared to CNY 6,201,822,654.41 at the beginning of the quarter, reflecting an increase of approximately 8.43%[28]. - The total equity attributable to shareholders of the parent company was CNY 4,811,338,468.58, an increase from CNY 4,720,007,506.83 year-over-year[31]. - The total liabilities increased to CNY 7,442,782,395.54, compared to CNY 6,902,937,712.34 in the previous year, indicating a rise of 7.8%[31]. Cash Flow - The net cash flow from financing activities increased by 620.76% year-on-year, primarily due to funds raised from convertible bonds[11]. - The net cash flow from investment activities was -868,984,903.03, compared to -165,221,647.72 in the previous year, indicating a significant increase in cash outflow for investments[34]. - Total cash inflow from financing activities reached 1,222,473,542.77, up from 215,712,556.85 in the same quarter last year, reflecting a strong increase in financing efforts[34]. - The cash and cash equivalents decreased to CNY 535,140,364.06 from CNY 750,695,835.79, indicating a decline of about 28.7%[27]. - The cash flow from operating activities was not detailed in the provided data, but the overall cash position reflects challenges in maintaining liquidity[34]. Research and Development - Research and development expenses increased due to the hiring of high-level industry talent and recent graduates, impacting profitability[9]. - The company plans to increase R&D investment in 2024, with 77 projects initiated during the year, including 59 in the first quarter[15]. - Research and development expenses rose to CNY 144,693,156.01, up 23.6% from CNY 117,069,572.72 in the previous year[30]. - The company aims to enhance its competitiveness through iterative updates on core equipment in the raw materials, formulations, and packaging sectors[15]. Market Strategy - The company plans to enhance market expansion, particularly in high-end international markets and Europe and the United States, to increase market share[12]. - The company aims to accelerate the launch of new products and improve internal efficiency to achieve positive growth in revenue and net profit[12]. - The company will establish an after-sales service center to enhance service quality and increase the share of parts and services in sales and net profit[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,273, with no preferred shareholders[18]. - The largest shareholder, Changsha Chutian Investment Group, holds 38.07% of the shares, totaling 224,706,614 shares[18]. - The top ten shareholders collectively hold significant stakes, with the second-largest being Hunan Caixin Jingxin Investment Partnership at 3.79%[18]. - The company has 48,701,873 restricted shares held by Changsha Chutian Investment Group, which are set to be released on November 3, 2023[21]. Corporate Developments - The company appointed a new Chief Technology Officer, enhancing its focus on research and product development[25]. - The company established a joint venture with China National Gold Group to create a radiation service center, aiming to provide high-end irradiation services for biopharmaceutical and medical equipment companies[16]. - The company successfully listed its convertible bonds on February 29, 2024, following regulatory approvals[24]. - The company is implementing new accounting standards starting in 2024, which may impact future financial reporting and analysis[36]. - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[35].

楚天科技股份有限公司 审 计 报 告 众环审字(2024)1100083号 审 计 报 告 众环审字(2024)1100083 号 楚天科技股份有限公司全体股东： 一、 审计意见 我们审计了楚天科技股份有限公司（以下简称"楚天科技"）财务报表，包括 2023 年 12 月 31 日的合并及公司资产负债表，2023 年度的合并及公司利润表、合并及公司现金流量 表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 楚天科技 2023 年 12 月 31 日合并及公司的财务状况以及 2023 年度合并及公司的经营成果 和现金流量。 二、 形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则，我们独立于楚天科技，并履行了职业道德方面的其他责任。我们相信，我们获 取的审计证据是充分、适当的，为发表审计意见提供了基础。 三、 关键审计事项 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事项。这 ...

楚天科技股份有限公司2023年年度报告全文 证券代码:300358 证券简称:楚天科技 公告编号:2024-027 号 债券代码:123240 债券简称:楚天转债 楚天科技股份有限公司 2023 年年度报告 ...

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2024-038 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 楚天科技股份有限公司 关于作废部分 2021 年限制性股票激励计划已授予尚未归属的 限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"楚天科技"或"公司"）于 2024 年 4 月 23 日召开第五届董事会第二十二次会议、第五届监事会第十九次会议，审议通过 了《关于作废部分 2021 年限制性股票激励计划已授予尚未归属的限制性股票的议 案》。现将相关情况公告如下： 一、本次激励计划已履行的相关审批程序 （一）2021 年 12 月 10 日，公司分别召开第四届董事会第二十六次会议、第 四届监事会第二十二次会议，审议并通过了《关于公司<2021 年限制性股票激励 计划（草案）>及其摘要的议案》、《关于公司<2021 年限制性股票激励计划实施 考核管理办法>的议案》等议案，公司独立董事对第四届董事会第二十六次 ...

| 证券代码:300358 | 证券简称:楚天科技 | 公告编号:2024-034 | 号 | | --- | --- | --- | --- | | 债券代码:123240 | 债券简称:楚天转债 | | | 楚天科技股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召 开第五届董事会第二十二次会议、第五届监事会第十九次会议，审议通过 了《关于公司 2023 年度利润分配方案的议案》，该议案尚需提交公司 2023 年年 度股东大会审议。现将相关事宜公告如下： 一、利润分配方案 根据中审众环会计师事务所（特殊普通合伙）审计确认，公司合并报 表 2023 年度实现的归属于母公司股东的净利润为 317,075,752.08 元，母 公司 2023 年度实现净利润 141,608,781.30 元。截至 2023 年 12 月 31 日 止，公司合并报表未分配利润为 2,055,039,909.23 元，母公司未分配利润 为 1,360,41 ...